1-3 of 3
Mark W Drummond, MB ChB, PhD FRCPath
Close
Sort by
Journal Articles

Safety and Clinical Activity of Combined Romidepsin and Azacitidine Therapy in High Risk Acute Myeloid Leukemia: Preliminary Results of the Romaza Trial

Charles Craddock, Eleni Tholouli, MD PhD, Samuel Munoz Vicente, MSc, Emmanouela Gbandi, BSc, MSc, MScM, PhD, Aimee E Houlton, BSc, MSc, Mark W Drummond, MB ChB, PhD FRCPath, Jiri Pavlu, MD, Paresh Vyas, DPhil, FRCP, FRCPath, MRCP, MRCPath
Journal: Blood
Blood (2017) 130 (Supplement 1): 2581.
https://doi.org/10.1182/blood.V130.Suppl_1.2581.2581
Published: 2017
Journal Articles

A Phase Ib Study to Assess the Safety and Tolerability of Ruxolitinib in Combination with Azacitidine in Patients with Advanced Phase Myeloproliferative Neoplasms (MPN), Including Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukaemia (AML) Arising from MPN (The Bloodwise / TAP PHAZAR Study on Behalf of the UK MPN CSG)

Mark W Drummond, MB ChB, PhD FRCPath, Claire N. Harrison, BMBCh, DM, FRCP, FRCPath, Samuel Munoz Vicente, MSc, Adam J Mead, MD PhD, Christina Yap, MSci, PhD CStat, Frederick Chen, FRCP, FRCPath, PhD, Srinivasan Narayanan, MBBS, MRCP, FRCPath, Dragana Milojkovic, MBBS, PhD, Leyre Navarro-Nunez, PhD, Steven Knapper, BMBCh, MRCP, MRCPath, DM
Journal: Blood
Blood (2017) 130 (Supplement 1): 1649.
https://doi.org/10.1182/blood.V130.Suppl_1.1649.1649
Published: 2017
Journal Articles

Clinical Activity in a Phase 1 Study of Blu-285, a Potent, Highly-Selective Inhibitor of KIT D816V in Advanced Systemic Mastocytosis (AdvSM)

Daniel J. DeAngelo, MD, Albert Thomas Quiery, MD, Deepti Radia, MD, Mark W Drummond, MB ChB, PhD FRCPath, Jason Gotlib, MD, William A Robinson, MD PhD, Elizabeth Hexner, MDMS, Srdan Verstovsek, MD PhD, Hongliang Shi, Terri Alvarez-Diez, Oleg Schmidt-Kittler, Erica Evans, PhD, Mary Ellen Healy, Beni B. Wolf, MD PhD, Michael W. Deininger, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 2.
https://doi.org/10.1182/blood.V130.Suppl_1.2.2
Published: 2017